• MDV3100 (Enzalutamide): Optimizing CRPC Research Workflows

  2026-05-23

  MDV3100 (Enzalutamide) is a cornerstone for dissecting androgen receptor signaling and resistance in prostate cancer models. This guide unpacks experimental best practices, troubleshooting, and the latest translational insights—empowering researchers to model castration-resistant prostate cancer (CRPC) with precision.

• Tofacitinib Repairs GM-CSF–Driven Inflammation in RA Macroph

  2026-05-22

  This study establishes tofacitinib (CP-690550) as a uniquely effective agent for reversing both inflammatory and mitochondrial dysregulation in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA) patients. By targeting STAT5 signaling and restoring mitochondrial function, tofacitinib outperformed anti-TNF, anti-IL6R, and metabolic-targeted therapies, advancing the understanding of immune modulation in RA.

• Sodium Phosphate Dibasic in Biological Assay Buffers: Protoc

  2026-05-22

  Sodium phosphate dibasic (Na2HPO4) is the gold-standard pH stabilizer for reproducible biological assay buffers and aquatic toxicity workflows. This article unpacks its protocol-critical roles, experimental enhancements, and troubleshooting strategies, drawing on recent eco-toxicological studies and best practices for molecular biology.

• Revisiting Sumatriptan Metabolism: CYP and MAO A Pathways Cl

  2026-05-21

  This study revisits the metabolic fate of sumatriptan, challenging the traditional view that monoamine oxidase A (MAO A) is the sole enzyme responsible for its biotransformation. Using recombinant human enzymes and HPLC-MS, the authors reveal that cytochrome P450 isoforms also contribute to sumatriptan metabolism, with significant implications for drug metabolism research and neuropharmacological modeling.

• Merimepodib (VX-497): Optimizing IMPDH Inhibition in Lab Ass

  2026-05-21

  This scenario-driven guide empowers biomedical researchers to overcome challenges in cell viability and antiviral assays by leveraging the validated specificity and reliability of Merimepodib (VX-497), SKU B1112. Drawing on recent literature and real-world laboratory scenarios, it demonstrates how careful protocol optimization and vendor selection with APExBIO's offering can yield reproducible, interpretable data.

• Fulvestrant (ICI 182,780): Applied Workflows in Breast Cance

  2026-05-20

  Fulvestrant (ICI 182,780) offers precise ER antagonism and MDM2 degradation, making it a foundational tool for modeling endocrine resistance and enhancing chemotherapy sensitivity in breast cancer research. This guide details actionable protocols, troubleshooting strategies, and practical integration of recent mechanistic insights.

• Alfuzosin HCl: Translational Impact in BPH Research and Beyo

  2026-05-20

  Explore how Alfuzosin Hydrochloride—a selective α1 adrenoceptor antagonist—enables translational researchers to bridge mechanistic discovery with clinical application in benign prostatic hyperplasia (BPH). This article unpacks the molecular rationale, experimental best practices, and competitive advantages of Alfuzosin HCl, with special focus on reproducibility, uroselectivity, and workflow integration for lower urinary tract research. Drawing from recent literature and APExBIO's product intelligence, we provide actionable protocol guidance and a forward-looking translational outlook.

• KX2-391 Dihydrochloride: Applied Workflows in Oncology & Vir

  2026-05-19

  KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) offers a dual mechanism that uniquely targets Src kinase and tubulin, unlocking new experimental avenues across cancer and HBV research. This article distills advanced workflows, troubleshooting strategies, and real-world insights—empowering researchers to maximize reproducibility and translational relevance.

• Hypoxia and Immunometabolism in Tumor Microenvironment: Mech

  2026-05-19

  This review dissects how hypoxia-driven immunometabolic reprogramming shapes the tumor microenvironment (TME) to promote tumor progression and immune evasion. It highlights the centrality of glucose metabolism in tumor-immune cell competition and discusses prospects for metabolism-targeted therapies.

• WP1066, JAK2/STAT3 Inhibitor: Workflow Solutions in Oncology

  2026-05-18

  WP1066 enables precise inhibition of JAK2/STAT3 signaling, empowering cancer and regenerative researchers to dissect pathway function, optimize cell-based assays, and troubleshoot resistance. This article delivers actionable workflow enhancements and protocol guidance rooted in recent experimental advances.

• Reserpine (N1867): Practical Guidance for Lab Applications

  2026-05-18

  Reserpine (SKU N1867) is a high-purity research compound used for controlled neurotransmitter depletion and antihypertensive mechanism studies. It is not suitable for diagnostic, clinical, or veterinary use and requires careful attention to solubility and storage parameters to ensure experimental consistency.

• COG133 Peptide Modulates miR-146a and Inflammation in Diabet

  2026-05-17

  The referenced study demonstrates that the ApoE-mimetic peptide COG133 enhances diabetic fibroblast migration, upregulates miR-146a, and reduces pro-inflammatory signaling, while also exhibiting antibacterial and antibiofilm activity. These findings highlight COG133's potential for improving wound healing outcomes in diabetes, offering new insight into miRNA-mediated regulation of inflammation and innate immunity.

• STING Agonist-1: Enhancing Innate Immunity in Cancer Researc

  2026-05-16

  STING agonist-1 empowers immunology and oncology labs to model and modulate the STING–CD40–TRAF2–IRF4 axis, driving advanced B cell activation workflows and tertiary lymphoid structure formation studies. Learn how to optimize assays, troubleshoot common pitfalls, and leverage new mechanistic insights from ESCC research for improved experimental outcomes.

• Stattic STAT3 Inhibitor: Applied Workflows in Cancer Researc

  2026-05-15

  Stattic, a small-molecule STAT3 inhibitor from APExBIO, empowers precise dissection of STAT3 signaling in cancer biology with robust in vitro and in vivo performance. This guide unpacks practical protocols, advanced applications, and troubleshooting insights for maximizing reproducibility in STAT3-dependent cancer models.

• Y-27632 in Precision Disease Modeling: Beyond Cytoskeletal C

  2026-05-15

  Explore how Y-27632, a selective ROCK inhibitor, empowers advanced disease modeling and patient-specific stem cell research. Discover its distinct role in modulating cytoskeletal dynamics and leveraging new iPSC-based platforms.

449 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page